BridgeBio Pharma (BBIO) Interest Expenses (2018 - 2026)

BridgeBio Pharma has reported Interest Expenses for 9 years, with the latest figure at $20.3 million in Q1 2026.

• Quarterly Interest Expenses fell 12.7% year-over-year to $20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.1 million (down 30.21% YoY) and the FY2025 annual result came in at $968.0 million, up 33.09% from the prior year.
• Interest Expenses rose to $20.3 million in Q1 2026 per BBIO's latest filing, from $9.4 million in the prior quarter.
• Over five years, Interest Expenses peaked at $205.3 million in Q2 2025 and troughed at $9.4 million in Q4 2025.
• A 5-year average of $37.2 million and a median of $20.6 million in 2023 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2022 and 2024: Interest Expenses tumbled 80.79% in 2022, then jumped 221.02% in 2024.
• Over 5 years, Interest Expenses stood at $20.0 million in 2022, then soared by 52.39% to $30.5 million in 2023, then sank by 56.98% to $13.1 million in 2024, then slipped by 28.03% to $9.4 million in 2025, then surged by 115.37% to $20.3 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $20.3 million, $9.4 million, and $62.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.